Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Andreas Underbjerg Raade1, Karen Middelbo Buch-Olsen1,2, Lars Lund2,3

  • 1Nuklearmedicinsk Afdeling, Odense Universitetshospital.

Ugeskrift for Laeger
|September 2, 2024
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma - A systematic review and meta-analysis.

Seminars in nuclear medicine·2026
Same author

Progression-free Survival Following Primary Staging with [<sup>18</sup>F]PSMA-1007-PET/ceCT Versus Na[<sup>18</sup>F]F-PET/ceCT in Prostate Cancer: Results from the PRISMA-PET Randomized Controlled Trial.

European urology open science·2026
Same author

DaRenCa risk score: A prognostic model for recurrence in clear cell renal cell carcinoma.

BJUI compass·2026
Same author

[Late sequelae after major urological surgery].

Ugeskrift for laeger·2026
Same author

Prognostic value of the SENTIREC-endo algorithm integrating sentinel lymph node and FDG-PET/CT in staging high-risk endometrial cancer.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Management of Lymph Node-Positive Renal Cell Carcinoma: Updated Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.

European urology·2026
Same journal

[Mosaicism as a cause of Cowden syndrome].

Ugeskrift for laeger·2026
Same journal

[Thyrotoxic crisis with cardiogenic shock].

Ugeskrift for laeger·2026
Same journal

[Mindfulness-based cognitive therapy in the treatment of depression].

Ugeskrift for laeger·2026
Same journal

[Fitness].

Ugeskrift for laeger·2026
Same journal

[Risk of developing cataract related to fluoroscopy].

Ugeskrift for laeger·2026
Same journal

[Obturator hernia with small bowel ileus presenting as hip pain in an elderly woman].

Ugeskrift for laeger·2026
See all related articles

Nuclear medicine imaging for prostate cancer has advanced, with PSMA-PET/CT showing high accuracy. While widely used for biochemical recurrence, more outcome data is needed for primary staging recommendations.

Area of Science:

  • Oncology
  • Radiology
  • Nuclear Medicine

Background:

  • Nuclear medicine imaging for prostate cancer has seen significant advancements.
  • Traditional methods like bone scans and bone-PET remain in wide application.
  • Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) is a newer, highly accurate imaging modality.

Purpose of the Study:

  • To review the current landscape of nuclear medicine imaging in prostate cancer.
  • To evaluate the role and limitations of PSMA-PET/CT in clinical practice.
  • To assess the alignment of nuclear medicine use in Denmark with clinical guidelines.

Main Methods:

  • A comprehensive literature review and survey of current practices.
  • Analysis of the diagnostic accuracy and clinical utility of various nuclear medicine techniques.

Related Experiment Videos

  • Examination of clinical guidelines and patient outcome data related to PSMA-PET/CT.

    • Main Results:

    • PSMA-PET/CT demonstrates high accuracy but lacks sufficient patient outcome data for primary staging treatment allocation.
    • Bone scans and bone-PET are still widely utilized in prostate cancer management.
    • Clinical guidelines and literature support the use of PSMA-PET/CT for biochemical recurrence detection.
    • Nuclear medicine examinations for prostate cancer in Denmark are consistent with clinical guidelines.

    Conclusions:

    • PSMA-PET/CT is a valuable tool for detecting prostate cancer recurrence.
    • Further research on patient outcomes is necessary to solidify PSMA-PET/CT's role in primary staging.
    • Current clinical guidelines support the appropriate application of PSMA-PET/CT in specific prostate cancer scenarios.